News For VRTX From The Last 14 Days Check below for free stories on VRTX the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 4, 2010
|
| 16:20 EDT |  | VRTX |
|
|
February 3, 2010
|
| 09:53 EDT |  | VRTX |
| | 08:18 EDT |  | VRTX |
| theflyonthewall.com: | Vertex Pharmaceuticals announces VX-809 cystic fibrosis drug Phase 2 results | | Vertex Pharmaceuticals announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis - CF - who are homozygous for the F508del mutation. VX-809 was well-tolerated across all four dose groups studied. In the trial, VX-809 showed a statistically significant decline in sweat chloride at both once-daily doses. Additionally, VX-809 demonstrated a dose response in change in sweat chloride across the four dose groups. On the basis of these results, Vertex plans to initiate a combination trial of VX-809 and VX-770, an investigational CFTR potentiator, in the second half of 2010. :theflyonthewall.com |
|
|
February 1, 2010
|
| 07:10 EDT |  | VRTX |
|
|
|
Subscribe for More Information